ABOUT

About the Journal
The Journal of Organoid & Bioscience, the official journal of the International Society of Organoid Research, is a distinguished open access, peer-reviewed international journal. It specializes in publishing groundbreaking research in the field of organoids, encompassing basic, translational, and related studies. The journal's commitment to high-quality research and its role in advancing the organoid field make it a vital resource for researchers, clinicians, and academics and industrial experts worldwide.

Aim and Scope
Aim
The primary aim of 'Journal of Organoid & Bioscience' is to establish a leading-edge forum for the dissemination and discussion of pioneering research in the field of organoid science. Our objective is to catalyze scientific innovation and advancement by presenting high-quality, peer-reviewed research that underscores the transformative potential of organoids in various domains of bioscience.

Scope
Fundamental Organoid Biology
Disease Modeling and Pathological Studies
Regenerative Medicine and Therapeutics
Drug Development and Testing
Translational and Clinical Research
Technological Innovations in Organoid Research
Ethical, Legal, and Social Implications (ELSI)
Interdisciplinary Approaches and Collaborations
Educational and Outreach Initiatives

Commitment
At 'Organoid & Bioscience', we are committed to ensuring the highest standards of research integrity and scientific excellence. We welcome contributions from diverse global perspectives and strive to create an inclusive environment that encourages dialogue, innovation, and the advancement of knowledge in organoid science and bioscience.

Editorial Board
Editor-in-Chief
Peter E. LOBIE
Tsinghua-Berkeley Shenzhen Institute (TBSI)
Prof. Peter E. Lobie is academician of the Royal Society of New Zealand, and Professor and Director of the Precision Medicine and Healthcare Research Center of Tsinghua-Berkeley Shenzhen Institute (TBSI). Professor Lobie is the founding chairman of ISoOR. He has been dedicated to study of targeted therapy of cancer for years, and has conducted pioneering research on factors leading to tumour. He is author of over 190 publications and an international authority on molecular mechanisms of hormone action with more than 9,000 citations and an h-factor of 53. Professor Lobie owns over 28 international patents, has obtained 24 national-level research funds, and been financed in projects development by internationally famous academic institutions such as National Research Foundation Singapore and Royal Society of New Zealand.

Associate Editor
Lingzhi WANG
The Cancer Science Institute of Singapore, National University of Singapore
Dr. Lingzhi Wang holds the position of Associate Professor at the Cancer Science Institute of Singapore, National University of Singapore. Additionally, he serves as an Executive member and Treasurer of the Pharmacological Society Singapore. Recently, he received the honor of being awarded a distinguished Visiting Professorship by the committee of the China-ASEAN Higher Education Collaboration and Exchange Week, which granted him the opportunity to participate in an Industry-Academia-Research Collaboration Event in Zhejiang, China.
Within the Department of Pharmacology at NUS, Dr. Wang is actively engaged in teaching two modules: Cancer Pharmacology for undergraduates and Anticancer Therapeutics for postgraduates. His research focuses on pioneering the development of innovative anticancer drugs, optimizing novel combination therapies for diverse cancer types, identifying promising anticancer lead compounds sourced from natural products, exploring preclinical and clinical cancer pharmacology, and spearheading the discovery of bio-fluid cancer biomarkers for early detection.
In addition to his dedication to research, he holds prestigious roles as an Associate Editor for internationally peer-reviewed journals, including Cancers, Frontiers in Pharmacology, and Frontiers in Oncology. His expertise is highly sought after, as he is frequently invited to conduct peer reviews for esteemed journals like Advanced Science, Advanced Materials, Seminars in Cancer Biology, and Trends in Pharmacological Sciences, among others.

Yi-Chin TOH
Queensland University of Technology
Yi-Chin Toh is an Australian Research Council Future Fellow and Professor at the Queensland University of Technology. She is trained as a chemical and tissue engineer, having obtained her B.Eng. and PhD from the National University of Singapore. She did her post-doctoral training at the Massachusetts Institute of Technology and A*STAR Institute of Bioengineering and Nanotechnology.
Yi-Chin is one of the field’s leading experts in developing micro-physiological systems for disease modelling and drug testing applications. Her works on animal alternative technologies have won accolades, such as the Global 3R Award (2019), and Lab on a Chip & Dolomite Pioneers in Miniaturization Lectureship Award (2022). Yi-Chin is a member of Scientific Advisory Committee of Lab on a Chip and AIP Biomicrofluidics. She is also a member of the Australian Research Council College of Experts.

Mingliang YOU
Hangzhou AimingMed Technologies Co., Ltd.
Dr. Mingliang YOU is a Ph.D. graduate in Pharmacology from the National University of Singapore, having published over 30 SCI papers and authored a monograph for the Royal Society of Chemistry Publishing House in the UK. He has successfully filed 18 patent applications, with 10 patents granted. In 2020, he founded Hangzhou AimingMed Technologies Co., Ltd., securing multiple rounds of funding. The company is a domestic leader and the only one in Hangzhou specializing in organoid technology. It has been actively involved in drafting international standards for organoid biobanks and serves as the Secretariat of the International Society of Organoid Research (ISoOR) in China. Leveraging cutting-edge organoid technology, AimingMed specializes in providing hospitals with advanced solutions for drug sensitivity testing and precise diagnosis and offers pharmaceutical enterprises a high-throughput platform for drug screening and efficacy evaluation. Prior to his entrepreneurial venture, Dr. YOU served as the Principal Investigator at the Key Laboratory of Oncology Pharmacology and Toxicology in Zhejiang Province and as the Deputy Director at the Institute of Oncology at the Affiliated Hangzhou Cancer Hospital of Zhejiang University School of Medicine.

Arindam BANERJEE
LifeSenz Cancer Research Labs
Dr. Banerjee currently serving as CEO and Director of LifeSenz Cancer Research Labs Mumbai and is a translational cancer biologist with more than 17 years across academia and industry set up at various international and national levels. His work expertise includes therapy resistance and cancer stem cells, altered metabolism, immunoncology and tumor microenvironment. He has contributed to multiple peer reviewed scientific publications, including senior author publication such as in Breast Cancer Research, PLOS One, Journal of Biological Chemistry, Cancer Research and got accolades at various international scientific meetings. Dr. Banerjee is also an expert in advanced in vitro and ex vivo cell modelling based platform development in cancer therapeutics field. Moreover, he has an extensive experience in scientific project management, academic tutoring and international collaborations. Dr. Banerjee received his PhD in Molecular Medicine from The University of Auckland, New Zealand and subsequent relevant work experience across various international locations such as UK, Singapore, New Zealand and India.